Carlos U. Corvera, M.D.
Associate Professor of Surgery
Chief, Hepatobiliary & Pancreas Surgery
Rather than isolated silos of care, we have a team approach, which makes a big difference in the overall care of the patients. Among competing therapies, patients always recieve the optimal one, regardless of which medical practice offers it.
Eric Nakakura, M.D., Ph.D. has been awarded a grant to study acquired mTOR resistance in pancreatic neuroendocrine tumors, the disease that caused the death of the late Steve Jobs.
A gift to the Hepatobiliary & Pancreas Surgery Program will lead to the discovery of new treatments and cures for diseases of the liver, biliary ducts and and pancreas.
The Hepatobiliary and Pancreatic Surgery (HPB) Program provides state-of-the-art treatment for patients with primary and metastatic cancers of the liver, gallbladder, bile duct and pancreas. The program also treats benign disease including cysts, biliary strictures and bile duct injuries.
Patients receive seamless multidisciplinary care from a team comprised of hepatobiliary and transplant surgeons, diagnostic radiologists, interventional radiologists, medical oncologists, hepatologists, gastroenterologists and anesthesiologists.
UCSF is one the few centers nationally that performs a large number of advanced laparoscopic liver procedures. For liver, gallbladder and bile duct cancer cases requiring major resections, transplant surgeons apply their expertise from living donor liver transplantation to perform complex reconstruction of the hepatic artery, portal vein or bile duct. This allows the HPB team to resect cancers involving major blood vessels which may be deemed inoperable at other centers.